Are we already able to assess our patients accurately for MI risk factors or is there another test that could provide more accuracy? Our guest today, Dr. Jeffrey Gulcher, chief scientific officer and co-founder of deCode Genetics tells host, Dr. Larry Kaskel about deCode MI. Learn how to use and interpret the results of the new decode MI test. What can you learn that you don't already know?
deCode MI: Another Tool to Assess Patient's MI Risk
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Are we already able to assess our patients accurately for MI risk factors or is there another test that could provide more accuracy? Our guest today, Dr. Jeffrey Gulcher, chief scientific officer and co-founder of deCode Genetics tells host, Dr. Larry Kaskel about deCode MI. Learn how to use and interpret the results of the new decode MI test. What can you learn that you don't already know?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Evolving Our View of the Coagulation Cascade and Stroke Management
0.25 credits
<p><span data-contrast="auto" xml:lang="EN-US">Evolving Our View of the Coagulation Cascade and Stroke Management</span><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p>
MinuteCE®
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
1.00 credits
<p>I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis</p>
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
1.25 credits
<p>Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
CME/CE
Impact of Barostim on Heart Failure Hospitalization
<p>Impact of Barostim on Heart Failure Hospitalization</p>
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
1.50 credits
<p>Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?